eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Winthrop Pharmaceuticals UK Ltd

One Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 554 831
E-mail: UK-medicalinformation@sanofi-aventis.com
Medical Information Direct Line: +44 (0)1483 554 101
Medical Information Fax: +44 (0)1483 554 831

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 17/05/2011
SPC Flagyl 500mg/100ml Solution for Infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/05/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   11-May-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



section 4.8 (undeisrable effect)

addition of aseptic meningitis and optic neuropathy/neuritis

 

Updated on 25/03/2011 and displayed until 17/05/2011
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
Date of revision of text on the SPC:   16-Mar-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company


Section 4.4 - brought in line with CCDS
- addition of info about use in patients with active or chronic severe peripheral or central nervous system disease due to the risk of neurological aggravation, as well side effects to look out for.
- warning about darkening of urine
- Cefuroxime info added and mutagenic potential.
Updated on 09/02/2011 and displayed until 25/03/2011
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   31-Jan-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.8 - Updated in line with company core data sheet:

Immune system disorders: fever added
Psychiatric disorders: depressed mood added
Eye disorders: clarification of duration of side effect
Gastrointestinal disorder: clarification of GI disturbances
Skin and subcut tissue disorders: flushing added
Updated on 19/01/2011 and displayed until 09/02/2011
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.9 - Overdose
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   04-Jan-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Flagyl Injection:

 

Section 4.1- wording changed to Flagyl is indicated in adults and children for the following indications…. No indications have changed.

 

Section 4.2.

Prophylaxis against anaerobic infection

Following text added-  Children < 12 years: 20-30mg/kg as a single dose given 1-2 hours before surgery. Newborns with a gestation age < 40 weeks: 10mg/kg body weight as a single dose before operation

 

Treatment of established anaerobic infections: 

 

Children > 8 weeks to 12 years of age: The usual daily dose is 20-30mg/kg/day as a single dose or divided into 7.5mg/kg every 8 hours. The daily dose may be increased to 40mg/kg, depending on the severity of the infection. Duration of treatment is usually 7 days.

 

Children < 8 weeks of age: 15mg/kg as a single dose daily or divided into 7.5mg/kg every 12 hours. In newborns with a gestation age < 40 weeks, accumulation of metronidazole can occur during the first week of life, therefore the concentrations of metronidazole in serum should preferable be monitored after a few days therapy.

 

Following guidance and information is new;

Bacterial vaginosis:

Adolescents: 400mg twice daily for 5-7 days or 2000mg as a single dose.

 

Urogenital trichomoniasis:

Adults and adolescents: 2000mg as a single dose or 200mg 3 times daily for 7 days or 400mg twice daily for 5-7 days

Children < 10 years: 40mg/kg orally as a single dose or 15-30 mg/kg/day divided in 2-3 doses for 7 days; not to exceed 2000mg/dose

 

Giardiasis:

> 10 years: 2000mg once daily for 3 days, or 400mg three times daily for 5 days, or 500mg twice daily for 7 to 10 days

Children 7 to 10 years: 1000mg once daily for 3 days

Children 3 to 7 years: 600 to 800mg once daily for 3 days

Children 1 to 3 years: 500mg once daily for 3 days

Alternatively, as expressed in mg per kg of body weight: 15-40mg/kg/day divided in 2-3 doses.

 

Amoebiasis:

> 10 years: 400 to 800mg 3 times daily for 5-10 days

Children 7 to 10 years: 200 to 400mg 3 times daily for 5-10 days

Children 3 to 7 years: 100 to 200mg 4 times daily for 5-10 days

Children 1 to 3 years: 100 to 200mg 3 times daily for 5-10 days

Alternatively, doses may be expressed by body weight: 35 to 50mg/kg daily in 3 divided doses for 5 to 10 days, not to exceed 2400mg/day

 

Eradication of Helicobacter pylori in paediatric patients: As a part of a combination therapy, 20mg/kg/day not to exceed 500mg twice daily for 7-14 days. Official guidelines should be consulted before initiating therapy

 

Section 4.5- following text added- Psychotic reactions have been reported in patients who are using metronidazole and disulfiram concurrently.

 

Section 4.9: following text added;

 

Single oral doses of metronidazole, up to 12g have been reported in suicide attempts and accidental overdoses. Symptoms were limited to vomiting, ataxia and slight disorientation. There is no specific antidote for metronidazole overdosage. In cases of suspected massive overdose, symptomatic and supportive treatment should be instituted.

 

Section 10- date changed to 04.11.2011

Updated on 22/04/2010 and displayed until 19/01/2011
Reasons for adding or updating:
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
Date of revision of text on the SPC:   03-Mar-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Change of ownership of licence
Updated on 24/09/2008 and displayed until 22/04/2010
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Date of revision of text on the SPC:   14-May-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company


Completely updated version of SmPC reflecting changes to sections 4.3, 4.5 and 4.8 as well as an update of format to QRD template.
Updated on 14/01/2002 and displayed until 24/09/2008
Reasons for adding or updating:
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction

Active Ingredients/Generics

 
   metronidazole